

Form PTO-1595 (Rev. 10/02) OMB No. 0651-0027 (exp. 6/30/2005) Tab settings ⇌ ⇌ ⇌ ▼ ▼ ▼ ▼ ▼ ▼ ▼		RECORDATION FORM COVER SHEET PATENTS ONLY		U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office	
To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.					
1. Name of conveying party(ies): Corautus Genetics, Inc. Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No		2. Name and address of receiving party(ies) Name: <u>Magnum Therapeutics, L.P.</u> Internal Address: _____ _____ _____ Street Address: <u>8395 Camino Santa Fe, Suite B</u> _____ _____ City: <u>San Diego</u> State: <u>CA</u> Zip: <u>92121</u> Additional name(s) & address(es) attached? ☐ Yes ☒ No			
3. Nature of conveyance: ☒ Assignment ☐ Merger ☐ Security Agreement ☐ Change of Name ☐ Other _____ Execution Date: <u>July 10, 2003</u>		4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date of the application is: _____ A. Patent Application No.(s) <u>08/658,961; 09/619,938;</u> <u>08/791,021; 08/791,218; 08/866,403; 09/837,079</u> B. Patent No.(s) <u>6,403,370; 6,051,218;</u> <u>6,551,588</u> Additional numbers attached? ☒ Yes ☐ No			
5. Name and address of party to whom correspondence concerning document should be mailed: Name: <u>Mark L. Chael, J.D., Ph.D.</u> Internal Address: <u>32nd Floor</u> _____ _____ Street Address: <u>300 South Wacker Drive</u> _____ _____ City: <u>Chicago</u> State: <u>IL</u> Zip: <u>60606</u>		6. Total number of applications and patents involved: <u>33</u> 7. Total fee (37 CFR 3.41).....\$ <u>1320.00</u> ☐ Enclosed ☒ Authorized to be charged to deposit account 8. Deposit account number: <u>13-2490</u>			
DO NOT USE THIS SPACE					
9. Signature. <u>Mark L. Chael, J.D., Ph.D.</u> <u>Mark L. Chael</u> <u>September 12, 2003</u> Name of Person Signing Signature Date Total number of pages including cover sheet, attachments, and documents: <u>14</u>					

Mail documents to be recorded with required cover sheet information to:
Commissioner of Patents & Trademarks, Box Assignments
Washington, D.C. 20231

CH \$1320.00 132490 08668961

Attachment to Assignment Recordation Form

Conveying Party: Corautus Genetics, Inc.
Receiving Party: Magnum Therapeutics, L.P.

Continuation of Item No. 4

<u>Patent Application No.</u>	<u>Attorney Case No.</u>	<u>Patent Application No.</u>	<u>Attorney Case No.</u>
60/197,734	96,2087-J	60/376,350	02-308
60/198,501	96,2087-K	08/597,524	P-UL-1932
60/287,850	96-2087-L	09/535,654	P-UL-4032
60/239,224	00-1104	PCT/US97/01465	FP-UL-2407
60/241,625	00-1130	PCT/US97/10218	96,2087-B
08/810,039	96,424-B	PCT/US97/23700	96,2087-D
09/779,570	96,424-H	PCT/US98/10330	96,2087-E
08/797,160	97,087	PCT/US01/23005	96,424-I
09/539,698	97,087-B	PCT/US02/12237	96,2087-O
08/789,886	96,2088	PCT/US98/03473	96,424-C
60/323,644	01-1207	PCT/US98/01301	97,087-A
60/347,707	01-1700	PCT/US97/23685	96,2088-A

ASSIGNMENT OF INVENTIONS, PATENTS AND INTELLECTUAL PROPERTY

Corautus Genetics Inc., a corporation organized under the laws of the State of Delaware, located at 6555 Nancy Ridge Drive, San Diego, California 92121 ("Assignor"), has certain rights, title, and interest in certain inventions as set forth on Exhibit "A" attached hereto and fully incorporated herein ("Inventions"), for which Assignor has certain rights, title and interest in patent applications filed with and patents granted by the patent offices as listed on Exhibit "A" ("Patents") and has certain rights in certain other intellectual property as listed on Exhibit "B" ("IP").

Assignor and Robert E. Sobol, M.D., an individual with an address of P.O. Box 1574, Rancho Santa Fe, California 92067 ("Assignee") are parties to that certain Separation Agreement and General Release of Claims, dated April 3, 2003 ("Agreement"), pursuant to which Assignor agreed to sell, transfer and assign, to the extent assignable, to an entity designated by Robert E. Sobol ("Assignee") certain intellectual property rights, including all of its right, title and interest in and to the Inventions, the Patents and the IP (to the extent Assignee has such rights) in exchange for the consideration set forth in the Agreement.

Assignee has designated Magnum Therapeutics Corporation as the entity to which Assignor shall assign the Inventions, Patents and the IP.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby irrevocably assigns, conveys and transfers to Assignee all of Assignor's worldwide right, title and interest, if any, in and to (a) the Inventions and Patents specified in Exhibit A, the IP property described on Exhibit B and all improvements and derivative works thereof, including without limitation all other worldwide patent applications and resulting Letters Patent that may be filed or issued related thereto, and all continuations, continuations-in-part, divisions, renewals, substitutes, extensions or reissues thereof, all foreign or international counterpart applications thereof, all reexaminations or reissuances thereof, the subject matter of all claims which may be obtained in every such patent, the scope of the specifications described in any of the foregoing, to the end of the term or terms for which such patents are or may be granted, reissued or reexamined (b) to the research reagents and hemophilia clinical materials listed in Exhibit C. Assignor further grants to Assignee rights of access at reasonable times and upon reasonable notice, together with the right to copy at Assignee's expense to all reasonably related written patent documents, research and development documentation, laboratory notebooks and grant related documents.

ALL ASSETS ASSIGNED HEREUNDER ARE "AS IS", SUBJECT TO ALL DEFECTS, ENCUMBRANCES, LIABILITIES AND LIMITATIONS.

ASSIGNOR MAKES NO WARRANTIES, EXPRESS OR IMPLIED, AS TO ANY INVENTION, PATENT OR IP ASSIGNED UNDER THIS ASSIGNMENT OF INVENTIONS, PATENTS AND INTELLECTUAL PROPERTY, INCLUDING WITHOUT LIMITATION AS TO OWNERSHIP OR TITLE. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF ANY SUCH INVENTIONS, PATENTS OR IP, OR THAT THE MANUFACTURE OR USE OF INVENTIONS, PATENTS OR IP WILL NOT INFRINGE ANY PATENT OR OTHER RIGHTS. ASSIGNOR SHALL NOT BE LIABLE FOR ANY CONSEQUENTIAL OR OTHER

m122.jpg

ATLANTA:4559573.6

PATENT**REEL: 013964 FRAME: 0497**

DAMAGES SUFFERED BY ASSIGNEE OR ANY OTHERS RESULTING FROM ANY SUCH INVENTION, PATENT OR IP.

Assignor hereby expressly reserves the right of reasonable access to and right to reference any of the foregoing as may be necessary or appropriate for any filing with the FDA, the NIH or any other governmental entity for the purpose of concluding any grant work or clinical trials related to any of the foregoing or responding to any questions or inquiries in connection with any of the foregoing.

Assignor hereby agrees to execute any documents or instruments necessary, and in a form acceptable, to Assignor to complete or confirm the transfer of rights granted herein. Assignee releases Assignor from all obligations and liabilities, whenever arising, with respect to such Inventions, Patents and IP. By execution below, Assignee acknowledges receipt of all items listed on Exhibit C which were received into Assignee's possession on June 11, 2003.

Assignor shall have no right or obligation to: (1) continue prosecution of patent applications that are part of the Property; (2) maintain any existing Patents that are part of the Property; (2) enforce any Patents; or (3) take any action in furtherance of prosecuting or exploiting patent applications or Patents.

IN WITNESS WHEREOF, Assignor has executed this Assignment effective as of July 14, 2003.

ASSIGNOR:

CORAUTUS GENETICS, INC., a Delaware corporation

By: 
Richard E. Otto, Chief Executive Officer

ASSIGNEE:

MAGNUM THERAPEUTICS, L.P., a California Limited Partnership

By: Magnum Therapeutics Corporation,

a California corporation, General Partner

By: 
Its:  President, CEO

Consented to:


Robert E. Sobol, M.D.

EXHIBIT "A"

INDEX TO FOREIGN PATENT FILES [MBHB]						
No.	Case No.	Title	Inventor	Serial No.	Vol.	Patent Issued Location
MINI-AD						
1	96,2087-B (PCT)	Mini Ad Vector Filed: 12/4/97	Zhang et al	PCT/US97/10218		RES 3-1
1.1	96,2087-B (PCT)	References to #1	Zhang et al	PCT/US97/10218		RES 3-1
1.2	96,2087-B (PCT)	References to #1	Zhang et al	PCT/US97/10218		RES 3-1
1.3	96,2087-B (PCT)	References to #1	Zhang et al	PCT/US97/10218		RES 3-1
2	96,2087-D (PCT)	Factor VIII Mini-Ad Vector Filed: 12/18/97 CASE WITHDRAWN PER EMILY MAIO 1/14/98	Josephs, et al			RES 3-1
3	96,2087-E (PCT)	Factor VIII Mini-Ad Vector Filed: 05/19/98	Zhang et al	PCT/US98/10330		RES 3-1
4	96,2087-F (EPO)					
5	96,2087-G (CAN)					
6	96,2087-H (JP)					
7	96,424-I (PCT)	Mini-Adenoviral Vector System for Vaccination Filed: 7/20/01				
8	96,2087-O	Mini-Ad Vector for Immunization Filed: 4/18/02		PCT/US02/12237		

PATENT

INDEX TO FOREIGN PATENT FILES [MBHB]						
No.	Case No.	Title	Inventor	Serial No.	Vol.	Patent Issued Location
CELL LINES						
9	96,424-C (PCT)	Adenovirus E-1 Complimenting Cell Lines Filed: 2/23/98	Ayares, et al	PCT/US98/03473		RES 3-1
10	96,424-D (EPO)	Adenovirus E-1 Complimenting Cell Lines	Ayares, et al.	98 908 661.6		RES 3-1
11	96,424-E (CAN)					
12	96,424-F (JP)					
DUAL-AD SYSTEM						
13	97,087-A (PCT)	AN ONCOLYTIC/IMMUNOGENIC COMPLEMENTARY-ADENOVIRAL VECTOR SYSTEM	Alemaný et al.	PCT/US98/01301		WO 98/35028 08/13/98 RES 3-1
14	97,087-C (EPO)					
15	96,424-D (JP)					
16	96,424-E (CAN)					
BASIC AD VECTORS						
17	96,2088-A (PCT)	Methods for Highly Efficient Generation of Adenoviral Vectors Filed: 12/19/97	Dai	PCT/US/97/2368 5		WO 98/32860 07/30/98 RES 3-1
17.1	96,2088-A (PCT)	References for #16	Dai	PCT/US/97/2368 5		WO 98/32860 07/30/98 RES 3-1

INDEX TO RADIATION SENSITIZATION PATENTS
[CAMPBELL & FLORES]

	UCLA Ref.	C&F Docket	Title	Inventor	Serial No.	Patent	Issued	Location
1.	LA 96-569-1	P-UL-1932	Tumor Radiosensitization using Gene Therapy; Filed: 2/2/96	McBride	US 08/597,524	US 6,051,218	4/18/00	RES 3-3
2.	LA 96-569-01	P-UL-1932	Tumor Radiosensitization using Gene Therapy [CIP 08/597,524; filed 1/23/98	McBride	08/597,524	LA 96-569-01		RES 3-3
3.	LA 96-569-2	P-UL-4032	Tumor Radiosensitization using Gene Therapy; filed 3/24/00	McBride	09/535,654	LA 96-569-2		RES 3-3
4.	LA 96-569-1	FP-UL-2407	Combined Radiotherapy and Immunotherapy to Treat Cancer [Filed: 1/31/97]	McBride	PCT/US97/01465			RES 3-3
5.	LA 96-569-1	FP-UL-3204	Combined Radiotherapy and Immunotherapy to Treat Cancer [Filed: 1/31/97]	McBride	Canada Pat. App: 2,244,841			RES 3-3
6.	LA 96-569-01	FP-UL-3205	Combined Radiotherapy and Immunotherapy to Treat Cancer [Filed: 1/31/97]	McBride	Europe Pat. App: 979040854			RES 3-3
7.	LA 96-569-1	FP-UL-3206	Combined Radiotherapy and Immunotherapy to Treat Cancer [Filed: 1/31/97]	McBride	Japanese Pat. App: 527808			RES 3-3
	LA 96-569-1	FP-UL-3896	Combined Radiotherapy and Immunotherapy to Treat Cancer [Filed: 1/31/97]	McBride	Hong Kong Pat. App. 99104559.7 (European Pat. No. 0 907 720)			RES 3-3

INDEX TO ADENOVIRAL VECTOR U.S. PATENT FILES [MBHB]

No.	Case No.	Title	Inventor	Serial No.	Vol.	Dates	Patent Issued	Location
MINI-AD								
1.1	96,424	Mini-Adenoviral Vector System (parent) Filed 5/31/96	Zhang, et al.	08/658,961	I	5/31/96 through 6/10/98		RES 3-2
1.2	96,424	Mini-Adenoviral Vector System (parent)	Zhang, et al.	08/658,961	II	6/12/98 through 2/26/01		RES 3-2
1.3	96,424	Mini-Adenoviral Vector System (parent)	Zhang, et al.	08/658,961	III	8/25/00 to		RES 3-2
2	96,424-G	Mini-Adenoviral Vector System for Vaccination (Continuation of 96,424) FILED: 7/20/00	Zhang, et al.	08/619,938				RES 3-2
3	96,2087	Factor VIII Mini-Ad Vector (CIP of 96,424) Filed 1/27/97	Josephs et al.	08/791,021				RES 3-2
4.1	96,2087-A	Factor VIII Mini-Ad Vector (CIP of 96,424) Filed 1/13/97	Josephs, et al.	08/791,218	I	1/31/97 through 4/99		RES 3-2
4.2	96,2087-A	Factor VIII Mini-Ad Vector (CIP of 96,424) Filed 1/13/97	Josephs, et al.	08/791,218	II	4/99 to 2/16/01		RES 3-2
5.1	96,2087-C	Mini-Ad Vector (CIP of 96,424 and 96,2087-A) Filed: 5/30/97; Amended 10/23/97	Zhang, et al.	08/866,403	I	8/21/97 to 1/19/99		RES 3-2
5.2	96,2087-C	Mini-Ad Vector (CIP of 96,424 and 96,2087-A) Filed: 5/30/97; Amended 10/23/97	Zhang, et al.	08/866,403	II	8/19/99 to 12/26/00		RES 3-2

INDEX TO ADENOVIRAL VECTOR U.S. PATENT FILES [MBHB]

No.	Case No.	Title	Inventor	Serial No.	Vol.	Dates	Patent Issued	Location
6	96,2087-I	Minimal Adenoviral Vector System for FVIII Gene Therapy (Cont of 96,2087-C) Filed: 4/18/01	Zhang et al	09/837,079				RES 3-2
7	96,2087-J	Development and Application of a Minimal-Adenoviral Vector System for Gene Therapy of Hemophilia A: Thrombosis and Haemostasis, 82(2): 562-571 (1999) [Provisional APPLICATION WITH NEW DATA, incorporated into 96,2087-L Filed: 4/18/00	Zhang, et al	60,197,734				RES 3-2
8	96,2087-K	Sustained High-Level Expression of Full-Length Human Factor VIII and Restoration of Clotting Activity in Hemophilic Mice Using Minimal Adenovirus Vector. <u>Blood</u> , 95(3): 820 (2/1/00) [Provisional, incorporated into 96,2087-L] Filed: 4/18/00	Balague, et al	60,198,501				RES 3-2
9	96,2087-L	Mini-Ad Vector and Methods of Using Same [Provisional Application; includes data from 96,2087 J & K, and the use of immunomodulators (i.e., anti-CD4 with mini-AD. Filed: 5/1/01	Fang and Hariharan	60/287,850				RES 3-2
PATENT								

INDEX TO ADENOVIRAL VECTOR
U.S. PATENT FILES [MBHB]

No.	Case No.	Title		Inventor	Serial No.	Vol.	Dates	Patent Issued	Location
10	MBHB00-1104	Mini-Ad Mediated Vaccine [Provisional App]	Recombinant Vaccine [Provisional App]	Fang	Prov: 60/239,224				RES 3-2
11	MBHB00-1130	HIV/HPV Mini-Ad Vaccine [Provisional App]		Fang	Prov: 60/241,625				RES 3-2
CELL LINES									
12.1	96,424-B	Adenovirus E1-Complementing Cell Lines (CIP of 96,424) Filed: 3/4/97		Ayares, et al.	08/810,039	I			RES 3-2
12.2	96,424-B	Adenovirus E1-Complementing Cell Lines (CIP of 96,424) Filed: 3/4/97		Ayares, et al.	08/810,039	II			RES 3-2
13	96,424-H	Adenovirus E-1 Complementing Cell Lines (Continuation of 96,424-B, which was unintentionally abandoned Filed: 2/8/01 with request to revive 96,424-B, which was granted		Ayares, et al	09/779,570				RES 3-2
DUAL-AD SYSTEM									
14	97,087	Oncolytic/Immunogenic Complementary Adenoviral System	Vector	Aleman, et al	08/797,160	I	2/10/97 through 5/30/00		RES 3-2

PATENT
REF : 013964 FRAME

INDEX TO ADENOVIRAL VECTOR U.S. PATENT FILES [MBHB]

No.	Case No.	Title	Inventor	Serial No.	Vol.	Dates	Patent Issued	Location
14.2	97,087	Oncolytic/Immunogenic Complementary Adenoviral Vector System Filed: 2/10/97; Cont. 5/22/02 Patent issued 6/11/02	Alemany, et al	08/797,160	II	8/11/00 through 2/12/01	US 6,403,370 B1	RES 3-2
15	97,087-B	Oncolytic/Immunogenic Complementary Adenoviral Vector System [Adds new data related to liver and prostate cancer along with DNA sequences] (CIP of 97,087) Filed: 3/31/00	Alemany, et al	09/539,698				RES 3-2
BASIC AD VECTORS								
16.1	96,2088	Methods for Highly Efficient Generation of Adenoviral Vectors Filed: 1/28/97	Dai	08/789,886	I	1/28/97 through 5/1/98		RES 3-2
16.2	96,2088	Methods for Highly Efficient Generation of Adenoviral Vectors Filed: 1/28/97	Dai	08/789,886	II	6/4/98 through 2/1/01		RES 3-2
17	MBHB 01-1207	Methods of Treatment with Viral Vectors (TGF-Beta blocker) Filed: 9/20/01		60/323,644				
18	MBHB 01-1700	Vaccine and Cancer Therapy Vectors (Genetic Dual Ad Contracts) Filed: 1/10/02		60/347,707				
	MBHB 02-308	Materials and Methods for the Production of Biological Compositions (Liposomes / PEG) Filed: 4/29/02		60/376,350				

REEL: 013964 FRAME: 0505

Exhibit B

A. All of Assignor's right to any of the following obtained by Assignor on June 8, 2000 from Baxter Healthcare Corporation or Baxter International, Inc. (collectively "Baxter") to the extent owned by Assignor on the date hereof

1. United States and foreign copyrights, whether registered or unregistered;
2. United States, state and foreign trademarks, services marks, logos, trade dress and trade names, whether registered or unregistered;
3. confidential ideas, trade secrets, technology, know-how, inventions (whether or not patentable) and improvements thereto, concepts, methods, processes, formulae, reports, data, customer lists, mailing lists, business plans or other proprietary information; and

which exclusively relate to the technology developed by Baxter and relating to the mini adenoviral vectors for gene therapy, and any good will relating exclusively thereto.

- B. Any (i) inventions which may have been made and in which Baxter owns rights pursuant to the Clinical Studies Agreement between McMaster University and Baxter dated April 4, 1996; and (ii) inventions relating to adenoviral vector which may have been made or which are made in the future, and in which Baxter owns rights pursuant to the July 1, 1996 agreement between Baxter and the Chinese Academy of Military Medical Services, but only to the extent (a) such were obtained from Baxter by assignment dated June 8, 2000 and (b) such are owned by Assignor.

EXHIBIT C**QC Material Transfer List**

Items	Lot Number	Container	Vials
A549E1-8 MCB	01-MCB-001	A549E1 MCB	158 (released)
MiniAdFVIII MVB	M3004-005	#5, #6, #7	212 (released)
MaxAdFVIII MVB	M3004-001		40 (released)
AdH β MVB	M3004-004	#2, #4	140 (released)
AdH β MVB	M3004-003	AdH β 1, 2, 3	212 (released)
MaxAdFVIII	M4003-012	#46, #45	34
MaxAdFVIII	M4003-011	#47	5
MaxAdFVIII	M4003-010	#48	19 (released)
MaxAdFVIII	M4003-009	#11, #12	36
MaxAdFVIII	M4003-008	F008, F009	39
MaxAdFVIII	M4003-007	F005	20
MaxAdFVIII	M4003-006	F003, F004	27 (released)
MaxAdFVIII	M4003-005	F002	4
MiniAdFVIII	M4003-004	A6	8 (released)
MiniAdFVIII	M4003-003	A5	5
MiniAdFVIII	M4003-002	A1	9
MiniAdFVIII	M4003-001	A4	1

Transferred by: _____

Date: _____

Received by: _____

Date: _____

EXHIBIT C**List 2: Research Material for DNA Vaccine-6-11-03**

- | | | | |
|---------------------------------|-------------------------|-----|---|
| 1. GT4602 | MaxAd HIV v3.0 | GNT | pGT2300 + pGT4601 (enhancer minus)
05/29/01, Nate; 0101-35 |
| 2. GT4606 | Ad Easy/HIV v3 FINAL | GNT | Final product for HIV v3.0 in AdEasy™ system
Bobby; 0058 |
| 3. GT4607 | MaxAd HIV v3.0.1 | GNT | pGT2300 + pGT4543 (enhancer minus) <i>previously</i>
GT4626Anthony; 0131-013 |
| 4. GT4626 | MaxAdHIV/Egfp | | |
| 5. MaxAdADHIV virus, | | | |
| 6. MaxAdGFP virus, | | | |
| 7. GT8051 | pMaxAdPSAE1-B7/INFg/GFP | | (made by Xiangming Fang) |
| 8. UPAR clone A9 p6 (cell line) | | | |
| 9. UPAR-3 A9 | | | |